Evidence map›Paper›PMID 38260213›Full record

ArticleAdvances in radiation oncology2024

Clinical and Dosimetric Risk Factors Associated With Radiation-Induced Lung Toxicities After Multiple Courses of Lung Stereotactic Body Radiation Therapy.

Xingzhe Li, Ellen Yorke, Andrew Jackson, Yujuan Yue, Charles B Simone, Aditya P Apte, Andreas Rimner, Daniel R Gomez, Narek Shaverdian, Daphna Y Gelblum and 2 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Advances in Radiation Oncology in 2023.Advances in radiation oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Xingzhe LiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ellen YorkeDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew JacksonDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Yujuan YueDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Charles B SimoneDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Aditya P ApteDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Andreas RimnerDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Daniel R GomezDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Narek ShaverdianDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Daphna Y GelblumDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abraham J WuDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Annemarie F ShepherdDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Purpose: Data are limited on radiation-induced lung toxicities (RILT) after multiple courses of lung stereotactic body radiation therapy (SBRT). We herein analyze a large cohort of patients to explore the clinical and dosimetric risk factors associated with RILT in such settings. Methods and Materials: A single institutional database of patients treated with multiple courses of lung SBRT between January 2014 and December 2019 was analyzed. Grade 2 or higher (G2+) RILT after the last course of SBRT was the primary endpoint. Composite plans were generated with advanced algorithms including deformable registration and equivalent dose adjustment. Logistic regression analyses were performed to examine correlations between patient or treatment factors including dosimetry and G2+ RILT. Risk stratification of patients and lung constraints based on acceptable normal tissue complication probability were calculated based on risk factors identified. Results: Among 110 eligible patients (56 female and 54 male), there were 64 synchronous (58.2%; defined as 2 courses of SBRT delivered within 30 days) and 46 metachronous (41.8%) courses of SBRT. The composite median lung V20, lung V5, and mean lung dose were 9.9% (interquartile range [IQR], 7.3%-12.4%), 32.2% (IQR, 25.5%-40.1%), and 7.0 Gy (IQR, 5.5 Gy-8.6 Gy), respectively. With a median follow-up of 21.1 months, 30 patients (27.3%) experienced G2+ RILT. Five patients (4.5%) developed G3 RILT, and 1 patient (0.9%) developed G4 RILT, and no patients developed G5 RILT. On multivariable regression analysis, female sex (odds ratio [OR], 4.35; 95% CI, 1.49%-14.3%; Conclusions: Our data suggest an acceptable incidence of G2+ RILT after multiple courses of lung SBRT. Female sex, synchronous SBRT, prior G2+ RILT, and higher composite lung V20 may be risk factors for G2+ RILT.

Identifiers

PMID38260213
PMCPMC10801636
OpenAlexW4379744404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.